Interactions between Malassezia and New Therapeutic Agents in Atopic Dermatitis Affecting Skin Barrier and...

Area of Science:

• Dermatology
• Microbiology
• Immunology

Background:

• Atopic dermatitis (AD) pathogenesis involves Malassezia yeast.
• Current AD treatments include biologics like anti-Interleukin 4 receptor alpha (anti-IL4Rα) and Janus kinase (JAK) inhibitors like ruxolitinib.
• The specific impact of Malassezia restricta on AD and its interaction with these therapies requires investigation.

Purpose of the Study:

• To investigate the effect of Malassezia restricta (M. restricta) on skin barrier function and inflammation in an in vitro atopic dermatitis (AD) model.
• To examine the interaction between M. restricta and AD therapeutic agents, specifically anti-IL4Rα and ruxolitinib.

Main Methods:

• An in vitro AD model was created using reconstructed human epidermis (RHE) stimulated with IL-4 and IL-13.
• RHE models were inoculated with M. restricta and treated with anti-IL4Rα or ruxolitinib.
• Histological and molecular analyses were conducted to assess skin barrier integrity, inflammation markers, and signaling pathways.

Main Results:

• M. restricta downregulated skin barrier components and ceramide-related molecules, effects reversed by anti-IL4Rα and ruxolitinib.
• M. restricta upregulated antimicrobial peptides, VEGF, Th2-related cytokines, and JAK/STAT pathway molecules, which were suppressed by the treatments.
• M. restricta aggravated skin barrier dysfunction and Th2 inflammation, diminishing the therapeutic efficacy of anti-IL4Rα and ruxolitinib.

Conclusions:

• Malassezia restricta exacerbates skin barrier impairment and Th2-driven inflammation in atopic dermatitis.
• The presence of M. restricta can reduce the effectiveness of key AD therapies, including anti-IL4Rα and ruxolitinib.
• Further research is needed to understand Malassezia's role in AD and to develop targeted therapeutic strategies.